Market capitalization | €10.49b |
Enterprise Value | €11.81b |
P/E (TTM) P/E ratio | 24.80 |
EV/FCF (TTM) EV/FCF | 23.76 |
EV/Sales (TTM) EV/Sales | 5.20 |
P/S ratio (TTM) P/S ratio | 4.62 |
P/B ratio (TTM) P/B ratio | 5.59 |
Dividend yield | 2.36% |
Last dividend (FY23) | €1.20 |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
11 Analysts have issued a Recordati forecast:
11 Analysts have issued a Recordati forecast:
Sep '24 |
+/-
%
|
||
Revenue | 2,269 2,269 |
12%
12%
|
|
Gross Profit | 1,544 1,544 |
10%
10%
|
|
EBITDA | 793 793 |
15%
15%
|
EBIT (Operating Income) EBIT | 633 633 |
15%
15%
|
Net Profit | 423 423 |
13%
13%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Recordati SpA engages in the research, development, manufacturing, and marketing of pharmaceuticals. It operates through the following segments: Specialty & Primary Care and Rare Diseases Pharmaceuticals. The Specialty & Primary Care segment is related to pharmaceutical chemicals business. The Rare Diseases Pharmaceuticals segment, which relates to the Rare Diseases treatment. The company was founded by Giovanni Recordati in 1926 and is headquartered in Milan, Italy.
Head office | Italy |
CEO | Robert Koremans |
Employees | 4,455 |
Founded | 1996 |
Website | www.recordati.it |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.